Tanezumab (RN624)

Status: Schwannomatosis Clinical Trial

Location: Massachusetts General Hospital
Brand: Pfizer
Alt Name: RN624
Drug Description: May Control Schwannoma tumors and Chromic Pain.

1. "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis" clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT04163419
2. "FDA Considers Tanezumab Application for Chronic OA Pain." The Rheumatologist https://www.the-rheumatologist.org/article/fda-considers-tanezumab-application-for-chronic-oa-pain/
3. "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis". https://investor.lilly.com/news-releases/news-release-details/us-fda-accepts-regulatory-submission-tanezumab-potential-first
4. "Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic" Pharmacological research, 2020 - Elsevier https://www.sciencedirect.com/science/article/abs/pii/S1043661819305912